3.31  -0.31 (-8.56%)		01-30 16:00
Open: 3.6 High: 3.6 Volume: 175,789		Pre. Close: 3.62 Low: 3.275 Market Cap: 2(M)

Short term
Mid term
Targets	6-month :	8.21	1-year :	10.93
Resists	First :	7.03	Second :	9.35
Pivot price	3.91
Supports	First :	3.27	Second :	2.72
MAs	MA(5) :	3.58	MA(20) :	4.41
	MA(100) :	6.58	MA(250) :	19.55
MACD	MACD :	-0.7	Signal :	-0.6
%K %D	K(14,3) :	1	D(3) :	0.7
RSI	RSI(14): 34.7
52-week	High :	236.78	Low :	3.27

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ACON ] has closed above bottom band by 7.7%. Bollinger Bands are 36.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	3.61 - 3.63	3.63 - 3.65
Low:	3.22 - 3.24	3.24 - 3.27
Close:	3.27 - 3.31	3.31 - 3.35

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Tue, 13 Jan 2026
What's Going On With Aclarion Stock Tuesday? - Aclarion (NASDAQ:ACON) - Benzinga

Tue, 13 Jan 2026
Debt-free Aclarion now holds $21.6M to grow its AI back pain tool - Stock Titan

Tue, 13 Jan 2026
Aclarion, Inc. Secures $10.4 Million in Common-Stock Financing to Strengthen Balance Sheet and Extend Operating Runway - Quiver Quantitative

Tue, 13 Jan 2026
Aclarion, Inc. Closes $10.4 Million Financing to Extend Cash Runway - TradingView

Sat, 10 Jan 2026
Aclarion Announces $10.4 Million Registered Direct Offering - The Globe and Mail

Thu, 08 Jan 2026
Aclarion's 2025 Nociscan Scan Volumes Hit Record High, Shares Surge 45% - Nasdaq

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Shares Out	-4 (M)
Shares Float	0 (M)
Held by Insiders	1.05e+006 (%)
Held by Institutions	671340 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	-6.65e+006
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	258.79
Profit Margin	0 %
Operating Margin	-9 %
Return on Assets (ttm)	666.1 %
Return on Equity (ttm)	-52.4 %
Qtrly Rev. Growth	67480 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-2 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0.01
Price to Sales	0
Price to Cash Flow	0

Dividend	31020
Forward Dividend	17420
Dividend Yield	937160%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.